elevated levels of autoantibodies and an increased expression of human leukocyte antigen (HLA) class II molecules on biliary epithelial cells have been observed
[1] [2] The slowed transit time through the digestive system means that stool remains in the colon for extended periods, allowing more water to be absorbed and resulting in harder, more difficult-to-pass stools
See efficacy data for IMCIVREE across age groups
[Learn More in MedlinePlus] Code History FY 2026 - No Change, effective from 10/1/2025 through 9/30/2026 FY 2025 - No Change, effective from 10/1/2024 through 9/30/2025 FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024 FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023 FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022 FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021 FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020 FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019 FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018 FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017 FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
Jastreboff, et al., 'Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA', Lancet , vol